{"id":"W2807978154","doi":"10.1136/annrheumdis-2018-eular.3646","title":"SAT0271 Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52-week treatment period","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital","funders":"Myriad Genetics; UCB Pharma; Pfizer; Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriatic arthritis; Ankylosing spondylitis; Secukinumab; Immunogenicity; Concomitant; BASDAI; Internal medicine; Rheumatoid arthritis; Gastroenterology; Pharmacokinetics; Psoriasis Area and Severity Index; Methotrexate; Adalimumab; Adverse effect; Pharmacology; Immunology; Antibody; Psoriasis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001552448,0.00038097,0.0006711104,0.0001757672,0.0005939542,0.00005712185,0.0003534302,0.0001070302,0.000300845],"category_scores_gemma":[0.0001052574,0.0002742934,0.000216168,0.0002555092,0.0008831616,0.0002502003,0.0001789933,0.0001438148,0.00002011965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004938933,"about_ca_system_score_gemma":0.0001067099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006087409,"about_ca_topic_score_gemma":0.00005669865,"domain_scores_codex":[0.9978933,0.0002930163,0.0006802849,0.0004193941,0.000127039,0.0005869677],"domain_scores_gemma":[0.9987893,0.00008121381,0.0003954674,0.0005631627,0.0001472371,0.00002363142],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01251693,0.02134699,0.5633205,0.002185186,0.005075451,0.00006758424,0.04072139,0.00009744865,0.05588834,0.001385172,0.000120652,0.2972743],"study_design_scores_gemma":[0.006268142,0.001455055,0.9753613,0.002876342,0.00009561015,0.00003029138,0.0007738614,0.0000143678,0.0124042,0.0002856796,0.00006421986,0.0003708702],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768142,0.02188419,0.000003893547,0.0001027404,0.0002121693,0.0005817871,0.0003024764,0.00003847362,0.00006006568],"genre_scores_gemma":[0.9991432,0.0004894747,0.000008337599,0.00004963189,0.000005081618,0.00003014981,0.0001580286,0.00002978924,0.00008625885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4120408,"threshold_uncertainty_score":0.9999709,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009129718896250853,"score_gpt":0.2401444432605067,"score_spread":0.2310147243642558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}